Inside-the-Beltway chatter has it that some members of the Republican caucus are getting ready to support Senator Dorgan’s drug importation amendment in the misguided belief that it will serve as a healthcare reform “poison pill.”
Not.
The theory is that if the Dorgan Organ passes, then Big Pharma will throw its weight against the legislation.
Not.
This strategy is ill-considered for a multitude of reasons. Let me mention three:
(1) Volume. Big Pharma has more immediate big fish to fry, most notably protection of the Non-Interference Clause and a future with many more Medicare-eligible seniors having their on-patent prescription medicines paid for via Part D. And filling the doughnut hole (another part of “the deal”) is a crucial part of this strategy. Immediate (and likely permanent) increases in volume trumps the many negatives of drug importation. Short sighted? Certainly. But these are public companies with patent expiry issues, reimbursement worries and questionable pipelines. Big Pharma – while against drug importation – won’t go to the mat at this stage in the process.
A vote for drug importation minus Secretarial Certification is a very big mistake – regardless of motivation.